Older adults continue to face high risks from vaccine preventable diseases, yet coverage rates for influenza, pneumococcal disease and other respiratory infections remain suboptimal in many Member States.

ECDC has launched a call for experts to join a new Scientific Expert Panel to support the development of technical guidance on RSV vaccination to protect adults. Applications must be submitted by 5 April 2026.

Immune imprinting, in which prior antigenic exposures biases recall toward dominant epitopes, constrains the breadth and durability of influenza vaccine protection.

‘A public health call to action: Europe needs a coordinated approach to ensure vaccination coverage at all stages of life, writes Professor Stefania Maggi.

The European 2025/26 influenza season is dominated by the influenza A(H3N2) virus, with most sequenced viruses belonging to subclade K, genetically drifted from the vaccine virus, raising concerns around vaccine effectiveness.

ESWI Board Florian Krammer is a virologist and vaccine developer. In his podcast viroLOGICAL he will talk about viruses on a weekly basis – from historical pandemics to current developments.

The ESCMID Vaccine Study Group (EVASG) is conducting a study aimed at understanding which barriers and interventions healthcare professionals consider most important for improving influenza vaccination uptake among healthcare workers.

Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare prothrombotic complication that occurs after adenoviral vector–based vaccination against coronavirus disease 2019.